All entries for: TScan Therapeutics

March 4, 2026

TScan Therapeutics

Neutral Outlook

Waltham, MA
51-200 employees

The outcome of these challenges on the IRA, and the effects of the IRA on our business and the healthcare industry in general are not yet known.

Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic
November 12, 2025

TScan Therapeutics

Neutral Outlook

Waltham, MA
51-200 employees

On May 12, 2025, the Trump Administration published Executive Order 14297, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which generally, among other things, directs the federal government to establish and communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.

Scroll to Top